Drugs / VGR-R01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05399069 | Sep 2022 → May 2024 | Bietti crystalline corneoretinal dystrophy | Beijing Tongren Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05694598 | Mar 2023 → Sep 2024 overdue | Bietti crystalline corneoretinal dystrophy | Shanghai Vitalgen BioPharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07586306 | Jun 2026 → Jul 2027 expected | Bietti crystalline corneoretinal dystrophy | Shanghai Vitalgen BioPharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06699108 | Dec 2024 → Dec 2026 expected | Bietti crystalline corneoretinal dystrophy | Shanghai Vitalgen BioPharma Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGR-R01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06699108 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “VGR-R01 is a novel AAV vector carrying the human CYP4v2 coding sequence.” NCT05399069 ↗ |
| Route | Other | “Subretinal injection of VGR-R01” NCT05399069 ↗ |